Lactobacillus reuteri Assists Engineered Bacteria That Target Tumors to Release PD‐L1nb to Mitigate the Adverse Effects of Breast Cancer Immunotherapy
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Programmed death protein‐ligand 1 (PD‐L1) inhibitors demonstrate significant antitumor efficacy by modulating T‐cell activity and inhibiting the PD‐1/PD‐L1 pathway, thus enhancing immune responses. Despite their robust effects, systemic administration of these inhibitors is linked to severe immune toxicity. To address this issue, we engineered a strain, REP, which releases PD‐L1 nanoantibodies (PD‐L1nb) to treat breast cancer and attenuate immunotherapy‐related side effects. REP selectively targets tumors and periodically releases PD‐L1nb within tumors via a quorum‐sensing lysis system. Administration of 108 colony‐forming units (CFU) of REP led to a substantial 52% reduction in tumor growth, achieved through the sustained release of PD‐L1nb. Importantly, there were no detectable lesions in other organs, with the exception of mild intestinal damage. Further, we explored the potential of a combined treatment using Lactobacillus reuteri (LR) and REP to alleviate intestinal inflammation. LR modulates the expression of inflammatory markers IL‐1β, IL‐6, and IL‐10 through the JNK pathway, reducing intestinal inflammation without compromising REP's antitumor efficacy. Consequently, we formulated a dual strategy employing an engineered strain and probiotics to reduce the adverse effects of immunotherapy in cancer treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, Yue et al. (2024) engineered a novel L. reuteri strain designed to selectively target tumors and release PD-L1 nanobodies in a breast cancer mouse model. By combining the two treatments, they decreased the adverse events of ICB treatment by alleviating intestinal inflammation.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Yue et al., 2024
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“However, systemic administration of PD-L1 inhibitors often leads to potent antitumor effectiveness accompanied by severe immune toxicity, with approximately 70% of patients experiencing adverse immune reactions such as rash, colitis, thyroid dysfunction, and hepatitis [3, 4].”
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396 · cited 1×
“Studies have demonstrated that PD-L1 expression is associated with triple-negative breast cancer [30–32], and PD-1/PD-L1 pathway inhibitors can induce durable clinical responses in some breast cancer patients with metastatic TNBC [33].”
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · cited 1×
“Studies have shown that immune checkpoint blockade may alter the immune balance in the gut, leading to a decrease in probiotics such as Akkermansia and Lactobacillus , and an increase in inflammatory microbes such as Bacteroides and Burkholderiales , thereby exacerbating colitis [37, 38].”
Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body
Cristofori, F., Dargenio, V. N., Dargenio, C., Miniello, V. L., Barone, M., & Francavilla, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.578386 · Cited by 912 · cited 1×
“Through interactions with the host immune system, probiotics can regulate the intestinal microenvironment and enhance the secretion of anti-inflammatory cytokines in the gut, thereby promoting repair of gastrointestinal inflammatory damage [13].”
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905 · cited 2×
“…coli target the tumor microenvironment through complex mechanisms, such as trapping in the chaotic tumor vasculature following systemic injection, tropism for compounds produced by tumors, tumor localization following inflammation, and protection from clearance by the immune system [7–9].”
InfluentialLactobacillus reuteri induces gut intraepithelial CD4 + CD8αα + T cells
Cervantes-Barragan, L., Chai, J. N., Tianero, M. D., Di Luccia, B., Ahern, P. P., Merriman, J., Cortez, V. S., Caparon, M. G., Donia, M. S., Gilfillan, S., et al. (2017) · Science · doi:10.1126/science.aah5825 · Cited by 896 · cited 1×
“…some of which activate aryl hydrocarbon receptors (AhR) in group 3 innate lymphocytes (ILC3s) and CD4 + T cells, down-regulating and differentiating ThPOK into CD4 + CD8 𝛼𝛼 + double-positive intraepithelial lymphocytes to reprogram intraepithelial CD4 + T cells into immunomodulatory T cells [42].”
Breast Cancer Immunotherapy: Facts and Hopes
Emens, L. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 863 · cited 1×
“Studies have demonstrated that PD-L1 expression is associated with triple-negative breast cancer [30–32], and PD-1/PD-L1 pathway inhibitors can induce durable clinical responses in some breast cancer patients with metastatic TNBC [33].”
Synchronized cycles of bacterial lysis for in vivo delivery
Din, M. O., Danino, T., Prindle, A., Skalak, M., Selimkhanov, J., Allen, K., Julio, E., Atolia, E., Tsimring, L. S., Bhatia, S. N., et al. (2016) · Nature · doi:10.1038/nature18930 · Cited by 784
Role of Lactobacillus reuteri in Human Health and Diseases
Mu, Q., Tavella, V. J., & Luo, X. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00757 · Cited by 744 · cited 1×
“Lactobacillus reuteri (LR) modulates the intestinal microenvironment to restore the intestinal symbiotic flora in inflammatory bowel disease and mitigates intestinal inflammation by suppressing the expression of pro-inflammatory factors in intestinal epithelial cells [14–17].”
Cited by
Microbial modulation as a game changer: Boosting immunotherapy efficacy in breast cancer
Xia, F., Yi, Q., Xu, Z., Zhou, Z., Tang, H., Zhang, K., & Yan, Y. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.006 · Cited by 27
Microbiota-centered interventions to boost immune checkpoint blockade therapies
Almonte, A. A., Thomas, S., & Zitvogel, L. (2025) · Journal of Experimental Medicine · doi:10.1084/jem.20250378 · Cited by 19
Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy
Sabeel, Z., & Zhao, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02456-x · Cited by 21
“Lactobacillus reuteri ( L. reuteri) , a natural component of breast milk, has been shown to suppress BC cell proliferation and modulate host immune responses [108].”
Nama, A. A., Sandeepa, G. M., Viswanath, B., & Mastan, A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177410 · Cited by 12
Covalent organic frameworks for cancer immunotherapy: mechanisms, applications, and prospects
Zou, Y., Chen, M., Chen, J., Wang, W., & Zheng, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1719005 · Cited by 9
Shen, P., Cui, W., Lin, J., Wang, Z., Li, Z., & Liu, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1716230 · Cited by 2
Self-citationLiu, J., Zhang, Y., Huang, Y., Li, X., Huang, X., Xing, X., & Zhang, C. Y. (2026) · Biotechnology Journal · doi:10.1002/biot.70253 · Cited by 2
Yuan, W., Jiang, X., Qin, J., Wang, S., Liu, M., Jin, J., Geng, F., Pan, X., & Zhang, J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101849 · Cited by 3
“Engineered bacteria Rosetta(pPD-L1nb) were constructed, and the pPD-L1nb expression was verified according to our previous report [17].”
Self-citationGeng, F., Yue, L., Du, M., Jin, J., Zhang, Q., Hu, W., Hao, N., Liu, S., Jiang, P., & Pan, X. (2026) · Biotechnology Journal · doi:10.1002/biot.70243 · Cited by 1
“Engineered bacteria can be programmed to function within the necrotic, hypoxic, and immunosuppressive tumor microenvironment [12, 13].”
Self-citationProgress and Prospects of Nanodelivery Systems in Metabolism‐Regulated mRNA Vaccines
Wang, W. J., Zhang, H., Ren, S., Li, R. U. N. Z. H. I., Chen, J. F., Zhang, B., Wang, J., Li, C. J., Gao, X., Tian, Y., et al. (2026) · Biotechnology Journal · doi:10.1002/biot.70278 · Cited by 1
“This approach enables durable, localized microenvironment remodeling and may potentially reduce systemic toxicity [162, 163].”
Self-citationScope of nanobodies in hepatopancreatobiliary oncology
Nayek, U., Sharma, T., Kashyap, V. K., Gadad, S. S., Yallapu, M. M., Cobos, E., & Chauhan, S. C. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104666
Saliani, N., Hejazi, M. S., Vahed, S. Z., Aghdam, E. M., Mori, Z., Hasheminejad, N., Parvar, M. D., Montazersaheb, S., & Ebrahimi, V. (2026) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2026.04.017
Serrano-García, L., Martínez-Salvador, E., Belda-Marco, A., Herrero-Oliva, C., Cortés, J., Llombart‐Cussac, A., & Fernández-Murga, M. L. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2697600
“207 Conceptually, metabolite/pathway targeting could also include enzyme-level interventions within microbiome–host metabolic interfaces relevant to TNBC biology (e.g., β -glucuronidase within the estrobolome, discussed previously), with the goal of improving mechanistic specificity and…”
Bacterial metabolic–immune reprogramming in cancer: from living vectors to engineered biofactories
Wu, J., Xu, L., Chen, Q., Yu, L., Liu, Z., & Xia, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115394
Advances in the design, mechanism and clinical translation of engineered bacteria in cancer therapy
Fu, H., 廖翔宇, Wang, Y., Ye, H., & Tian, J. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2026207
Metadata
- Authors
- Yue, L., Geng, F., Jin, J., Li, W., Liu, B., Du, M., Gao, X., Lü, J., & Pan, X.
- Affiliations
- Binzhou Medical University (CN)
- Corresponding author
- Geng, Feng
- Pan, Xiaohong
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2024-12
- Volume
- 19
- Issue
- 12
- Pages
- e202400428-e202400428
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W4405727760
- Cited by
- 14
- References
- 45
- Citations by year
- 2026: 9 · 2025: 5
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biotechnology Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Natural Science Foundation of Shandong Province (ZR2022MC121)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- Lactobacillus reuteri, engineered bacteria, breast cancer, immune checkpoint inhibitors, immunotherapy toxicity, probiotics, intestinal inflammation, JNK signaling, IL-1β, interleukin-6, IL-10, tumor growth inhibition
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Breast Neoplasms, Female, Humans, Immunotherapy, Mice, Inbred BALB C, Cell Line, Tumor, Mice, Limosilactobacillus reuteri, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.